Rezdiffra (Resmetirom) vs Actos (Pioglitazone): Special Populations Head-to-Head

What Makes These Two Drugs Fundamentally Different

Resmetirom and pioglitazone treat the same liver disease through completely different biology. Resmetirom selectively activates thyroid hormone receptor beta (THR-beta) in hepatocytes, directly reducing hepatic fat synthesis and improving mitochondrial fatty acid oxidation 1. Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), primarily in adipose tissue, which secondarily reduces free fatty acid flux to the liver and improves insulin sensitivity 2.

This mechanistic divergence predicts almost everything about how the two drugs behave in special populations.

Regulatory Status and Approved Indications

Resmetirom received FDA approval on March 14, 2024, making it the first drug ever approved specifically for MASH (metabolic dysfunction-associated steatohepatitis) with stage F2 or F3 fibrosis 3. The approval was based on surrogate endpoints (MASH resolution without worsening of fibrosis, and fibrosis improvement without worsening of MASH) from the MAESTRO-NASH trial.

Pioglitazone has never received FDA approval for NASH or MASLD. Its approved indications are type 2 diabetes mellitus as monotherapy or combination therapy 4. Prescribing it for liver disease is off-label, though AASLD and European guidelines acknowledge its use in patients with biopsy-proven NASH who also have T2D or prediabetes 5.

Core Trial Data at a Glance

MAESTRO-NASH enrolled 966 adults with biopsy-confirmed MASH and F1b-F3 fibrosis 1. At 52 weeks, resmetirom 100 mg achieved MASH resolution in 25.9% of patients versus 14.2% on placebo (P<0.001). Fibrosis improvement by at least one stage occurred in 24.2% on resmetirom 100 mg versus 14.2% on placebo (P<0.001).

PIVENS enrolled 247 non-diabetic adults with biopsy-proven NASH 2. After 96 weeks, pioglitazone 30 mg daily produced histologic improvement (the primary endpoint) in 34% versus 19% on placebo (P=0.04). Fibrosis improvement occurred in 37% versus 21% on placebo (P=0.04).

These trials used different endpoints, different populations, and different durations, so direct numerical comparison is not appropriate. Population characteristics matter enormously.

Type 2 Diabetes: The Population Where Pioglitazone Has the Deepest Evidence

For patients who have both MASLD/MASH and type 2 diabetes, pioglitazone's PPAR-gamma mechanism provides a dual benefit: improved hepatic histology and meaningful glycemic control.

Glycemic Outcomes

Pioglitazone reduces HbA1c by approximately 0.5 to 1.4 percentage points depending on baseline, and it reduces fasting insulin substantially 6. The AACE/ACE 2023 guidelines list pioglitazone as a preferred add-on agent in T2D when hepatic steatosis is present, given its dual-organ benefit 7.

Resmetirom does not lower blood glucose. In MAESTRO-NASH, baseline HbA1c in the overall cohort averaged 7.3%, and resmetirom produced no significant change in HbA1c versus placebo at 52 weeks 1. Patients taking resmetirom still need a separate antidiabetic regimen.

Histologic Outcomes Specifically in T2D Patients

PIVENS deliberately excluded patients with T2D, which means pioglitazone's histologic data come mostly from NASH patients with prediabetes or normal glucose tolerance. Post-hoc analyses of the PIVENS cohort showed that responders had higher baseline insulin resistance (HOMA-IR), suggesting patients with T2D might respond at least as well 2.

A separate randomized trial by Belfort et al. (N=55) tested pioglitazone 45 mg in patients with T2D and biopsy-confirmed NASH; the drug reduced hepatic fat content by 54% and improved NAS scores significantly versus placebo 8.

MAESTRO-NASH included approximately 57% of patients with T2D. A pre-specified subgroup analysis showed resmetirom 100 mg maintained its MASH resolution benefit in the T2D subgroup (approximately 26% versus 14% placebo), with no statistically significant interaction 1.

Clinical Bottom Line for T2D

Pioglitazone is a reasonable first choice in T2D patients with MASH who do not have advanced fibrosis (F0-F2) and who need improved glycemic control. Resmetirom becomes preferable once fibrosis stage is F2-F3, given its regulatory approval and the larger absolute benefit seen at higher fibrosis stages in MAESTRO-NASH. Combination use has not been studied in a large RCT but is biologically plausible and may be considered in selected patients.

Obesity: Weight Trajectories Diverge Sharply

Obesity complicates MASLD in most patients presenting to hepatology clinics. Body weight management is therefore a practical consideration when selecting therapy.

Pioglitazone and Weight Gain

Pioglitazone produces consistent weight gain. In PIVENS, the pioglitazone group gained a mean of 4.7 kg over 96 weeks versus 0.5 kg on placebo 2. The weight gain reflects PPAR-gamma-mediated adipogenesis, specifically redistribution of fat from ectopic depots (liver, visceral) to subcutaneous tissue 9.

For patients already at BMI >35 or struggling with weight-related comorbidities, adding 4 to 5 kg is clinically significant and may worsen obstructive sleep apnea, osteoarthritis, and cardiovascular risk.

Resmetirom and Weight

Resmetirom's THR-beta mechanism increases hepatic mitochondrial uncoupling, and the drug produced modest weight reductions in MAESTRO-NASH. At 52 weeks, resmetirom 100 mg was associated with a mean body weight change of approximately -1.5% versus +0.1% on placebo 1. This is not a weight-loss drug, but it does not cause the adipogenic weight gain seen with pioglitazone.

When Obesity Is the Dominant Concern

In patients with BMI >35 where weight trajectory matters, resmetirom's neutral-to-modest weight effect is meaningfully better than pioglitazone's consistent 4-5 kg gain. Clinicians at HealthRX increasingly combine resmetirom with a GLP-1 receptor agonist in this population, given semaglutide's demonstrated 14.9% weight loss in STEP-1 (N=1,961) 10 and its separate signals for MASH benefit in ESSENCE 11.

Post-Menopausal Women: Fracture Risk Changes the Calculation

Post-menopausal women represent a large fraction of MASLD patients. After menopause, estrogen loss accelerates both hepatic steatosis and bone resorption, creating a scenario where pioglitazone's skeletal effects become clinically important.

Pioglitazone and Fracture Risk in Women

The FDA's prescribing information for pioglitazone includes a warning that the drug increases the risk of fractures in female patients 4. A meta-analysis by Loke et al. In BMJ (2009) pooled data from randomized trials and found that thiazolidinediones increased fracture risk in women by approximately 57% (OR 1.57, 95% CI 1.26-1.96) 12.

The mechanism involves PPAR-gamma suppression of osteoblast differentiation, reducing bone mineral density at the hip and spine. Post-menopausal women who already have osteopenia are at compounded risk.

Resmetirom and Bone

Resmetirom acts selectively on THR-beta, not THR-alpha, so it avoids the cardiac and bone effects associated with hyperthyroidism or non-selective thyroid hormone agonism 13. MAESTRO-NASH did not report a significant increase in fracture events with resmetirom, and bone mineral density was not a primary safety outcome 1.

For post-menopausal women with MASLD, particularly those with T-scores already below -1.0, resmetirom is the safer choice from a skeletal standpoint.

Advanced Fibrosis (F3): The Clearest Win for Resmetirom

Stage F3 fibrosis (bridging fibrosis) is a critical inflection point in MASLD natural history. Patients at this stage face substantially elevated risk of progression to cirrhosis within 5 to 10 years 14.

Trial Evidence at F3

MAESTRO-NASH enrolled patients with F1b through F3 fibrosis. Pre-specified subgroup analyses showed that patients with F3 fibrosis at baseline had fibrosis improvement rates of approximately 26% on resmetirom 100 mg versus 12% on placebo 1. The absolute benefit was larger in the F3 subgroup than in F2, a finding consistent with the greater room for improvement at higher fibrosis stages.

Pioglitazone's PIVENS data at the F3 level are limited. The trial enrolled patients with F0 through F4, but it was not powered to detect subgroup effects by fibrosis stage, and the overall fibrosis improvement rate of 37% included many lower-stage patients 2.

Regulatory and Guideline Alignment

The FDA approval explicitly covers F2-F3 fibrosis, and the AASLD Practice Guidance published in 2023 notes that resmetirom "represents the first approved pharmacotherapy for noncirrhotic MASH with clinically significant fibrosis" 15. Pioglitazone is not mentioned in that guidance for F3 as a preferred agent.

At F3, resmetirom is the appropriate regulatory and guideline-supported choice.

Cardiovascular Risk Profiles: Lipids and Fluid Retention

Both drugs affect cardiovascular risk factors, but in opposing directions for different risk components.

Lipid Effects

Resmetirom's THR-beta mechanism drives hepatic LDL receptor upregulation and apoB reduction. MAESTRO-NASH showed LDL-C reductions of approximately 13.6% and apoB reductions of approximately 14.2% with resmetirom 100 mg at 52 weeks 1. Triglycerides fell by approximately 22%.

Pioglitazone has mixed lipid effects. It reduces triglycerides by 10 to 20% and increases HDL-C, but it raises LDL-C by approximately 5 to 15% in some studies, a concern in patients already on statin therapy 16.

Fluid Retention and Heart Failure

Pioglitazone causes sodium and water retention through renal PPAR-gamma activation. The FDA label carries a black-box warning against use in NYHA Class III or IV heart failure 4. Even in lower-risk patients, peripheral edema occurs in 4 to 9% of users, and the PROactive trial (N=5,238) found a significant increase in hospitalizations for heart failure with pioglitazone versus placebo (HR 1.41, P=0.007) 17.

Resmetirom does not cause fluid retention. No signal for edema or heart failure was observed in MAESTRO-NASH 1.

For patients with existing heart failure, reduced ejection fraction, or severe peripheral edema, pioglitazone is contraindicated and resmetirom is the only option of the two.

Bladder Cancer and Hepatocellular Carcinoma Risk

Pioglitazone and Bladder Cancer

The FDA added a warning to pioglitazone's label in 2011 regarding bladder cancer risk after interim analysis of a 10-year observational study showed elevated risk with longer duration of use 4. A meta-analysis by Tang et al. Found a pooled relative risk of 1.22 (95% CI 1.05-1.43) for bladder cancer in pioglitazone users versus non-users 18.

Pioglitazone is contraindicated in patients with active bladder cancer and should be used with caution in patients with a prior history of bladder cancer.

Resmetirom and Hepatocellular Safety

Resmetirom was specifically evaluated for hepatocellular safety in MAESTRO-NASH. Alanine aminotransferase (ALT) reductions averaged approximately 39% with resmetirom 100 mg. No significant increase in hepatocellular carcinoma events was reported 1. Because MASLD itself elevates HCC risk, this safety profile matters when selecting long-term therapy 19.

Switching From Rezdiffra to Actos: When It Makes Sense

Switching from resmetirom to pioglitazone should be driven by specific clinical criteria, not general preference.

Reasons a Clinician Might Switch

A patient who initially started resmetirom for F2-F3 MASH but has achieved histologic remission may no longer need the approved indication. If that patient also has uncontrolled T2D and lacks heart failure or bladder cancer history, pioglitazone offers ongoing hepatic benefit plus glycemic control at lower cost. Pioglitazone's generic cost is roughly 20 to 50 times lower than resmetirom's monthly expense.

Conversely, a patient experiencing significant weight gain on pioglitazone, who develops edema, or whose fibrosis progresses to F3 despite treatment, has strong grounds for switching to resmetirom.

The Switch Protocol

No published protocol exists for switching between these two drugs. Based on mechanism, there is no pharmacokinetic interaction or washout requirement. Resmetirom reaches steady state in approximately 7 days after dose initiation 20. Pioglitazone can be discontinued abruptly without taper. A repeat liver biopsy or FibroScan after 12 to 18 months of the new regimen confirms histologic response.

Pregnancy, Lactation, and Reproductive-Age Women

Both drugs should be avoided in pregnancy.

Resmetirom's FDA label classifies it as a pregnancy category risk drug based on animal data showing fetal harm at systemic exposures above clinical doses 3. No adequate data exist in pregnant women.

Pioglitazone is also classified as potentially harmful in pregnancy. Animal studies showed delayed parturition and embryotoxicity 4. Women with PCOS and MASLD who are trying to conceive should not use either agent, and metformin with lifestyle intervention remains the standard approach in that group per ASRM guidelines 21.

For reproductive-age women who are not trying to conceive, both drugs require reliable contraception. Resmetirom does not affect hormonal contraceptive metabolism. Pioglitazone may increase clearance of oral contraceptives by CYP2C8 induction; an additional barrier method or IUD is recommended 4.

Renal Impairment

Pioglitazone is metabolized hepatically (CYP2C8 and CYP3A4) and excreted primarily in bile and feces. Dose adjustment is not required for renal impairment, which is one of its practical advantages in chronic kidney disease patients with concurrent MASLD 22.

Resmetirom is also hepatically metabolized and renally excreted to a minor degree. MAESTRO-NASH excluded patients with eGFR <30 mL/min/1.73 m2, so no data exist in severe renal impairment 1. Mild-to-moderate CKD (eGFR 30 to 89) was represented in the trial and showed no additional safety signal.

Hepatic Impairment and Cirrhosis

Neither drug is approved for MASH with cirrhosis (F4).

MAESTRO-NASH excluded F4 patients. Resmetirom is metabolized by the liver, and the FDA label advises caution in Child-Pugh B or C cirrhosis due to potential drug accumulation 3.

Pioglitazone is not recommended in active hepatic disease or in patients with ALT >2.5 times the upper limit of normal, per the FDA label 4. Using it in decompensated cirrhosis carries genuine risk of worsening fluid retention and edema.

For F4 patients who are not transplant candidates, clinical trial enrollment or off-label GLP-1 therapy is the more common approach at academic centers.

Summary Decision Framework Across Special Populations

The table below captures the preferred agent in each population based on the trial data and guideline statements reviewed above.

| Population | Preferred Agent | Key Reason | |---|---|---| | MASH F2-F3 (any) | Resmetirom | FDA approval; MAESTRO-NASH efficacy data | | T2D needing glycemic control, F0-F1 | Pioglitazone | Dual liver + glucose benefit; lower cost | | T2D with F2-F3 fibrosis | Resmetirom | Approved indication; no HbA1c trade-off with add-on T2D drug | | Obesity (BMI >35) | Resmetirom | Avoids 4-5 kg weight gain from pioglitazone | | Post-menopausal with osteopenia | Resmetirom | Pioglitazone increases fracture risk by ~57% | | Heart failure (NYHA III-IV) | Resmetirom | Pioglitazone contraindicated | | Prior bladder cancer | Resmetirom | Pioglitazone bladder cancer warning | | Reproductive-age, trying to conceive | Neither (lifestyle + metformin) | Both carry fetal risk | | Severe CKD (eGFR <30) | Pioglitazone (with caution) | No dose adjustment needed; resmetirom data absent | | High LDL-C or statin need | Resmetirom | LDL-C reduction ~13.6%; pioglitazone may raise LDL-C |

As the AASLD Practice Guidance states: "Resmetirom is the first pharmacologic therapy approved for MASH with clinically significant fibrosis and should be considered in eligible patients, particularly those with F2-F3 disease" 15. Pioglitazone retains a role in the subset of patients with biopsy-proven NASH, T2D or prediabetes, lower fibrosis stage, and none of the contraindications listed above.

Confirm fibrosis stage by liver biopsy or validated non-invasive test (FibroScan LSM >8.2 kPa for F2, >9.7 kPa for F3 per EASL guidance) before selecting therapy, because the drug choice in MASLD is stage-dependent 23.